Ohio DEA DATA 2000 One-and-a-Half-Day Waiver Training: Wooster, Ohio: April 06-07, 2018
- Registration Closed
Ohio DEA DATA 2000
One and a Half Day Waiver Training
Day 1: 8-Hour ASAM DATA 2000 Course
Friday, April 06, 2018
8:30 am - 5:30 pm
Gault Liberty Center
104 Spink Street
Wooster, Ohio, 44691
DAY 2: 4-Hour OhioMHAS Implementation Training
Saturday, April 07, 2018
8:30 am - 12:30 pm
Gault Liberty Center
104 Spink Street
Wooster, Ohio, 44691
This course is offered in partnership with the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and Substance Abuse and Mental Health Service Administration (SAMHSA). The curriculum for this course has been specifically designed for Ohio licensed physicians, nurse practitioners, and physician assistants.
Welcome to the Ohio DEA DATA 2000 One and a Half Day Waiver Training. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.
The 8-hour section of the training provided by the American Society of Addiction Medicine (ASAM) covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This course is SAMHSA-supported.
The 4-hour section of the training provided by OhioMHAS is required to receive your reimbursement and will include training from experts around Ohio that will enhance the prescriber’s knowledge about opioid prescribing and buprenorphine policies (e.g., low-dose prescribing according to federal and state guidelines and DEA guidance on documentation).
Once you have completed the entire day and a half training, return to the ASAM e-Learning Center and complete the necessary steps listed in the "content" tab to obtain your reimbursement. If you have any questions, please contact education@ASAM.org.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.
This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.
For NPs (CE Credit through AANP): Click Here
For PAs (AAPA Category 1 CME Credit): Click Here
Funding for this conference was made possible (in part) by the Ohio Opioid STR Project- 1H79TI080261-01 grant from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. |
Key:
Complete
Next
Failed
Available
LockedClick here for additional resources.
CME Information and Disclosure Listing
Date of Release: July 2015 Approved Through: July 2018
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
| Catherine Friedman, MD, FAPA, FASAM Chair | None | ||
Edwin A. Salsitz, MD, FASAM | None | ||
Herbert Malinoff, MD, FACP, FASAM | None | ||
Noel Ilogu, MD, MRCP | None | ||
John Tanner, DO, FASAM | Reckitt Benckiser OREXO BDSI | Honorarium
Honorarium Honorarium | Speaker
Speaker Speaker and Consultant |
ASAM Buprenorphine Program Planning Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Dan Alford, MD, MPH | None | ||
Andrew J. Saxon, MD | UpToDate | Royalties | Section Editor, Drug Use Disorders |
Colleen LaBelle, BSN, RN-BC, CARN | None | ||
Edwin Salsitz, MD, FASAM | None | ||
Jeffrey D. Baxter, MD | None | ||
Kelley Saia, MD | None | ||
Sharon Levy, MD, MPH | None | ||
Paula J. Lum, MD, MPH | None | ||
ASAM Buprenorphine Course Faculty
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Edwin Salsitz, MD, FASAM | None | ||
Andrew J. Saxon, MD | UpToDate | Royalties | Senior Editor, Drug Use Disorders |
Colleen LaBelle, BSN, RN-BC, CARN | None | ||
Dan A. Alford, MD, MPH | None | ||
Jeffrey D. Baxter, MD | None | ||
Kelley Saia, MD | None | ||
Sharon Levy, MD, MPH | None | ||
Paula J. Lum, MD, MPH | None | ||
Sarah Bagley, MD | ASAM Millennium Fellowship Award | Partial Salary Support | Awardee |
Alexander Y. Walley, MD, MSc | None | ||
ASAM CME Committee Reviewers
Name | Nature of Relevant Financial Relationship | |||
Commercial Interest | What was received? | For what role? | ||
Adam J. Gordon, MD, MPH, FACP, FASAM | None | |||
Herbert Malinoff, MD, FACP, FASAM | None | |||
Funding for this conference was made possible (in part) by the MHA-18-MEDDIR-DATA 2000 WAIVER-19 grant from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. |
At the conclusion of this activity, learners should be able to:
- Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with medications
- Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
Licensed physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
Claiming CME Credit
- Under the “Contents” tab locate the step “Complete Post-Course CME Evaluation”
- Fill out the survey by clicking the blue “Fill out Survey” button
- Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window
- Submit the evaluation (the next box should activate, and the CME evaluation box should turn green with a white check mark)
- Click the button “Claim Medical Credits” in the box titled “Download CME Certificate”
- Choose the type of credit (Physician or Non-physician) and click submit
- Click the button “View/Print Certificate” to save or print your certificate
- Pro tip: If you ever lose your certificate, you can come back to the ASAM e-Learning Center and view it on your Transcript (found on Dashboard)
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
